Litigation Details for Pfizer Inc. v. Rubicon Research Private Ltd. (D. Del. 2024)

Pfizer Inc. v. Rubicon Research Private Ltd. (D. Del. 2024)

Docket	1:24-cv-00626	Date Filed	2024-05-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	11,083,724
Link to Docket	External link to docket

Details for Pfizer Inc. v. Rubicon Research Private Ltd. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-05-23				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Rubicon Research Private Ltd. (D. Del. 2024)

Last updated: June 6, 2026

Pfizer Inc. v. Rubicon Research Private Ltd. 1:24-cv-00626 Litigation Summary and Patent Analysis

Executive summary: 1:24-cv-00626 is an active federal patent case in which Pfizer Inc. is the plaintiff and Rubicon Research Private Ltd. is the defendant. The matter is at an early stage, with no definitive claim construction, no final merits ruling, and no dispositive judgment reflected in the docket information available here. The practical risk for Rubicon is that Pfizer will use the asserted patents and any Orange Book listings tied to the relevant Pfizer product to frame infringement theories centered on manufacture, formulation, or method-of-use activities aligned with the defendant’s proposed generic or lifecycle product. For licensing and litigation strategy, the case posture indicates time spent on pleadings, early procedural steps, and likely motion practice rather than a completed litigation record.

What is Pfizer Inc. v. Rubicon Research Private Ltd. 1:24-cv-00626 about?

Short answer: The case is a U.S. patent infringement action filed by Pfizer against Rubicon Research Private Ltd. No final adjudication is available in the information provided here, so the substantive focus is determined by the claims and patents asserted in the complaint and the responses and defenses raised in the answer and any early motions.

Which patents are asserted in 1:24-cv-00626?

Short answer: The patents-in-suit are not identifiable from the information provided in this prompt. Without the asserted patent numbers and claim sets, infringement analysis cannot be completed at a claim-by-claim or limitation-by-limitation level.

What causes of action are typically pleaded in this posture?

Cases of this type commonly include:

• Direct infringement and/or induced infringement based on activities related to manufacturing or commercialization.
• Claims tied to regulatory submissions (often framed through the Orange Book reference drug, but the specific regulatory pathway and submission are not identified in the information provided here).
• Willfulness allegations if Pfizer pleads knowledge and deliberate copying.

What is the procedural posture of 1:24-cv-00626?

Short answer: The case is active and early. The docket number 1:24-cv-00626 indicates it was filed in 2024 and remains in process with litigation steps occurring after the complaint filing.

Typical early-stage milestones in 2024-filed patent cases

Common procedural steps include:

• Service of complaint and summons
• Answer and affirmative defenses
• Initial disclosures (if ordered under the court’s rules)
• Rule 12 practice or early motion practice (if any)
• Claim construction scheduling (Markman) if not yet underway

What is the strongest infringement theory Pfizer usually uses in Rubicon-type cases?

Short answer: Pfizer typically frames infringement around how the defendant’s product or manufacturing process practices the asserted patent claims, using documentary evidence tied to regulatory submissions, technical descriptions, and manufacturing evidence.

How infringement is usually mapped to patent claim elements

When courts evaluate infringement, claim scope is applied to facts such as:

• Composition and physical/chemical properties for formulation patents
• Dosage strength, release profile, and excipient system for drug product patents
• Process parameters for manufacturing method patents
• Therapeutic regimen steps for method-of-use patents

Where Rubicon’s role matters

If Rubicon is alleged to participate in contract research, synthesis, scale-up, or manufacturing activities, Pfizer’s theory often relies on:

• Contract manufacturing arrangements
• Technical transfer or process documentation
• Source and destination evidence linking Rubicon to the accused product

Which defenses are likely raised by Rubicon Research Private Ltd.?

Short answer: Early defenses in Hatch-Waxman-adjacent and standard patent infringement cases often include non-infringement, invalidity, and procedural defenses, with invalidity targeting novelty, non-obviousness, and claim indefiniteness if pleaded.

Common invalidity attacks

• Prior art obviousness and lack of inventive step
• Anticipation by single references
• Obviousness combinations
• Written description and enablement issues (for some case types)
• Indefiniteness and claim scope disputes

Settlement dynamics

In many Pfizer generic and lifecycle disputes, settlement leverage depends on:

• Strength of the asserted independent claims
• Prior art positioning against dependent claims
• Ability to design around claim elements
• Exposure from injunctive relief risks tied to market entry timing

When does Pfizer Inc. v. Rubicon Research Private Ltd. matter for generic market entry?

Short answer: The commercial impact is tied to the patent expiration dates and any regulatory exclusivities attached to the relevant Pfizer product. This prompt does not provide the product name or the Orange Book entry, so exact entry dates cannot be computed.

What to look for to estimate generic entry risk

Litigation-to-market mapping requires:

• Orange Book “listed patents” for the reference drug (drug product, method-of-use, and formulation patents)
• Expiration dates (including pediatric exclusivity and PTA impacts where applicable)
• Whether the case involves Paragraph IV or other challenge types (not identifiable here)

What Orange Book status applies to the asserted Pfizer product?

Short answer: The Orange Book status cannot be determined from the information provided here because the specific Pfizer product and Orange Book listing are not identified.

Why Orange Book status drives litigation leverage

Orange Book listing status affects:

• Whether infringement is tied to a statutory framework
• Whether an FDA submission is the basis of infringement allegations
• Timelines for market exclusivity and entry triggers

How strong is Pfizer’s patent estate in disputes like this?

Short answer: Strength depends on the asserted patents and their remaining term, claim breadth, and prior art vulnerability. No asserted patent numbers are available in the prompt, so no strength ranking can be made.

Typical patent-estate patterns for Pfizer lifecycle strategies

In drug product and lifecycle portfolios, Pfizer often asserts:

• Formulation patents (excipients, ratios, particle size, polymorphs)
• Manufacturing/process patents (steps, controls, impurities)
• Method-of-use patents (dosage regimens, patient selection)

What claim types usually dominate cases at this stage?

Short answer: Early-stage outcomes often turn on:

• Whether the asserted claims are broad enough to cover the accused activity
• Whether Pfizer’s theory relies on technical facts that Rubicon can rebut with process differences
• Whether invalidity arguments target independent claims early

Candidate claim categories that Pfizer commonly asserts

• Independent composition claims
• Process claims for manufacturing or purification
• Method-of-use steps

What litigation issues could slow down or accelerate the case?

Short answer: The next inflection points are procedural and technical: claim construction scheduling, early evidentiary disputes, and any attempt to narrow claims or contentions.

Procedural accelerants

• Prompt claim construction
• Narrowing of infringement contentions
• Coordination of expert reports and technical tutorials

Procedural slowdowns

• Expanded discovery due to multiple accused products or multiple manufacturing sites
• Disputes over claim term construction that affect trial scope
• Motion practice over admissibility of technical evidence

Are there any settlements or injunction outcomes tied to 1:24-cv-00626?

Short answer: The information provided does not include any settlement agreement, consent judgment, stipulated dismissal, or injunction order.

What commercial exposure does the case create for Rubicon and for Pfizer?

Short answer: Commercial exposure depends on whether Rubicon is supplying or enabling an accused product that competes with a Pfizer drug at risk of exclusivity loss. That product identity is not included here, so the exposure can only be framed structurally.

Exposure channels

• Competitive entry delay or design-around pathways
• Licensing leverage and non-infringement positioning
• Potential damages and attorneys’ fees exposure if willfulness is pleaded and supported

Key Takeaways

• 1:24-cv-00626 is an active patent litigation between Pfizer Inc. and Rubicon Research Private Ltd.
• The case posture is early, with no final merits outcome provided in the prompt.
• Actionable infringement and invalidity analysis requires the asserted patent numbers and the reference drug, which are not included in the information supplied here.
• The commercial impact hinges on remaining patent term, Orange Book listed patents, and any regulatory submission linkage.

FAQs

1. What patents are asserted in Pfizer v. Rubicon 1:24-cv-00626?
2. Is 1:24-cv-00626 a Paragraph IV Hatch-Waxman case, and what FDA submission triggered it?
3. What is the earliest potential claim construction or trial date in 1:24-cv-00626?
4. Which company controls prosecution or defense strategy for Rubicon in 1:24-cv-00626?
5. Could a settlement in 1:24-cv-00626 affect launch timing for an accused generic or lifecycle product?

References

1. Pfizer Inc. v. Rubicon Research Private Ltd., No. 1:24-cv-00626 (U.S. federal court docket).